false
0002030763
0002030763
2026-07-27
2026-07-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): July 27, 2026
DATAMEDS
AI, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-42530 |
|
93-3264234 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
3000
Bayport Drive
Suite
950
Tampa,
FL 33607
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (844) 203-6092
Wellgistics
Health, Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.0001 par value per share |
|
MEDS |
|
The
Nasdaq Capital Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01. Other Events.
On
July 27, 2026, DataMeds AI, Inc. issued a press release announcing that the record date for the distribution of the Dream Bowl 2026 Meme
Coin has been updated to August 7, 2026.
A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description
of Exhibit |
| 99.1 |
|
Press release dated July 27, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
July 28, 2026 |
DATAMEDS AI, INC. |
| |
|
|
| |
By: |
/s/
Prashant Patel |
| |
|
Prashant
Patel, President |
Exhibit 99.1
DataMEDS AI Announces Updated August 7, 2026 Record
Date for Distribution of Dream Bowl 2026 Meme Coin to Stockholders
AMPA, FL / ACCESS Newswire
/ July 27, 2026 / DataMEDS AI, Inc., (NASDAQ:MEDS, “DataMEDS,” or the “Company”), a health information technology
leader implementing EinsteinRx™ artificial intelligence prescription drug routing into blockchain-enabled smart contracts
platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey, today announced
an updated record date for the distribution of the Dream Bowl 2026 Meme Coin (https://www.biconomy.com/exchange/DREAM1_USDT) to
DataMEDS stockholders. On December 3, 2025, DataMEDS announced that it would distribute one (1) Dream Bowl 2026 Meme Coin for every one
(1) share of DataMEDS Health common stock held as of a designated record date. On July 20, 2026, DataMEDS previously set a new record
date of July 31, 2026 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin. Today, the Company further updated
the record date to August 7, 2026.
Holders of DataMEDS common
stock as of the new record date of August 7,2026 will be entitled to receive fifty (50) Dream Bowl 2026 Meme Coins for each share of DataMEDS
common stock that they hold. DataMEDS will distribute (or coordinate with DataMEDS’s transfer agent to distribute) any necessary
notices and forms to stockholders to obtain each holder’s digital wallet information to allow such holders to receive their Dream
Bowl 2026 Meme Coins. The distribution date (the “Distribution Date”) will be determined by subsequent resolution in coordination
with DataVault AI, Inc. (NASDAQ:DVLT).
As of the date of this press
release, DataMEDS has 2,847,198 common shares outstanding. Certain stockholders holding approximately 1,533,930 common shares, representing
a majority of the outstanding common shares, have entered into lock-up agreements that preclude the sale of their shares into the market
for at least ninety (90) days from today’s date. There are currently 919,465 DataMEDS common shares deposited in Depository Trust
& Clearing Corporation (DTCC) available for trading. There are no debt or preferred equity securities of the Company that are eligible
to convert into free trading common shares at the current time. There is a total of 80,826 cash warrants outstanding, each with a fixed
exercise price of $35.00 per share, that are currently eligible to be exercised into free trading common shares. Investors should refer
to the Company’s filings with the Securities and Exchange Commission for additional information regarding the Company’s capitalization
and outstanding securities.
About DataMeds AI, Inc.
DataMeds AI, Inc. (formerly
Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent
and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates
the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™
into the Health Lives Here Mobile application and Tollo Health.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include,
without limitation, statements regarding the proposed corporate name change to DataMeds AI, Inc.; the proposed rebranding of the Company’s
Pharmacy and Pharmacy Services division as Corexa Health; the Company’s proposed transaction with DataVault AI Inc., Scilex Holding
Company, EOS Holdings and HealthBridge Advisors; the anticipated timing, structure, terms and completion of such transaction; the satisfaction
or waiver of closing conditions; the receipt of stockholder approval and any other required approvals; the Company’s anticipated
business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial
intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI,
PharmacyChain, Health Lives Here and related platforms; the Company’s ability to empower patients to access, manage, control or
monetize health data; the anticipated benefits of the Company’s technology platforms, strategic relationships and business combinations;
the Company’s capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company’s
ability to maintain compliance with Nasdaq listing standards; and the Company’s liquidity, capital resources and ability to fund
operations.
Forward-looking statements
are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause
actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others,
the risk that the proposed name change may not be approved by stockholders or otherwise completed; the risk that the proposed transaction
may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived;
risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption,
scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory,
wearable-device and digital health technologies; risks related to healthcare privacy, cybersecurity, data ownership, data monetization
and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company’s
liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional
capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks
affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other
risks described in the Company’s filings with the Securities and Exchange Commission.
Forward-looking statements
speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law.
DataMEDS AI Media Contact
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: jlambert@rubensteinpr.com
DataMEDS AI Investor Contact
Investor Relations: IR@wellgisticshealth.com